• Avere Therapeutics agreed to merge into Nasdaq-listed NextCure in an all-stock deal, with closing targeted for 2H 2026.
• The combined company is expected to operate as Avere Therapeutics and trade under ticker AVRX.
• Hansoh Pharmaceutical granted Avere a global ex-China license for HS-20118 (AVR-001), with up to USD 120 million upfront.
• Additional consideration includes up to USD 2.18 billion in milestones and mid-single to low-double digit royalties on sales.
• Hansoh also subscribed for Avere convertible notes in a private placement; post-close stake seen at 30%-40% fully diluted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260714-12243841), on July 14, 2026, and is solely responsible for the information contained therein.